首页> 外文期刊>Ophthalmology >Immunologic graft rejection in descemet's stripping endothelial keratoplasty and penetrating keratoplasty for endothelial disease
【24h】

Immunologic graft rejection in descemet's stripping endothelial keratoplasty and penetrating keratoplasty for endothelial disease

机译:Decemet剥离内皮角膜移植术和穿透性角膜移植术治疗内皮病的免疫移植排斥反应

获取原文
获取原文并翻译 | 示例
           

摘要

Objective: To evaluate and compare the cumulative incidence and risk factors for first-episode immunologic graft rejection in Descemet's stripping automated endothelial keratoplasty (DSAEK) and penetrating keratoplasty (PK) and to identify potential risk factors for rejection. Design: Retrospective chart review. Participants: All patients who underwent PK or DSAEK for endothelial disease at the Department of Ophthalmology, North Shore LIJ, between January 2004 and June 2010. Methods: One hundred sixty-nine PK cases and 122 DSAEK cases were reviewed. All patients had a minimum of 3 months of follow-up, with median follow-up of 36 months in the PK group and 29 months in the DSAEK group. Main Outcome Measures: Cumulative incidence of first-episode immunologic graft rejection in PK and DSAEK cohorts. Risk factors for graft rejection were reviewed. Results: Cumulative incidence of rejection was not significantly different between the DSAEK and PK cohorts (P<0.1324). However, among patients without glaucoma, the risk of rejection in PK was higher than that in DSAEK (hazard ratio [HR], 5.56). Prior incisional glaucoma surgery imparted a 3.15 times greater risk of rejection regardless of transplant type. Phakic patients were more likely to experience rejection than patients with a posterior chamber intraocular lens (HR, 3.23; P<0.0266), but not more likely than those with an anterior chamber intraocular lens or who were aphakic. Graft failure occurred within 6 months in 31% of PK rejections and none of the DSAEK rejections. Conclusions: Descemet's stripping automated endothelial keratoplasty and PK did not show a statistically significant difference in the incidence of rejection; however, among nonglaucomatous eyes, there were significantly fewer rejections in those that underwent DSAEK. Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article.
机译:目的:评估和比较Descemet剥离自动内皮角膜移植术(DSAEK)和穿透性角膜移植术(PK)中首发免疫移植排斥的累积发生率和危险因素,并确定潜在的排斥危险因素。设计:回顾性图表审查。参加者:2004年1月至2010年6月间在北岸利吉亚州眼科接受PK或DSAEK内皮病治疗的所有患者。方法:回顾了169例PK例和122例DSAEK例。所有患者至少接受了3个月的随访,PK组中位数随访36个月,DSAEK组中位数随访29个月。主要观察指标:PK和DSAEK人群中首发免疫移植排斥反应的累积发生率。审查了移植排斥的危险因素。结果:DSAEK和PK队列的排斥反应累积发生率无显着差异(P <0.1324)。然而,在没有青光眼的患者中,PK排斥的风险高于DSAEK(风险比[HR],5.56)。不论何种移植类型,先前的切开性青光眼手术均具有3.15倍的排斥风险。有晶状体眼的患者比有后房人工晶状体的患者更有可能出现排斥反应(HR,3.23; P <0.0266),但没有比有前房人工晶状体或无晶状体的患者更容易出现排斥反应。 31%的PK拒绝率和6个月的DSAEK拒绝率均在6个月内发生移植失败。结论:Descemet的剥离自动角膜内皮移植术和PK在排斥反应发生率上没有统计学上的显着差异。然而,在非青光眼中,接受DSAEK的人的排斥反应明显减少。财务披露:作者对本文讨论的任何材料均没有所有权或商业利益。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号